PD5 Inhibitor and Endothelial Receptor Antagonist in PAH

In both of these large randomized clinical trials, the study drugs seem to be relatively well tolerated in both groups. And hospitalizations due to PAH were most significantly impacted. The approach to the ambition with initial combination therapy being superior to initial monotherapy always makes me wonder if I start two drugs at the same time. Even yesterday in my continuity clinic, I told the patient, we need to do one thing at a time so we know what's making you better or worse.